---

---

tags : Dermatitis    entities : Abbvie inc.   

save search

---

Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 1.41% | O: 2.24% H: 0.0% C: -0.8%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 1.6% | O: -3.43% H: 6.21% C: 6.21%
VTRS | News A | $11.55 1.67% 1.65% 7.2M |

Health Technology

| -2.12% | O: -0.25% H: 1.1% C: -0.17%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 2.67% | O: -0.05% H: 0.43% C: -0.27%
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -4.79% | O: -0.08% H: 0.04% C: -0.35%
BHC | $8.56 0.35% 0.0% 2M |

Health Technology

| -17.77% | O: 0.38% H: 0.0% C: -7.27%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| -0.07% | O: 0.77% H: 1.63% C: 0.35%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 1.11% | O: 0.84% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 5.56% | O: 0.18% H: 0.3% C: 0.19%
eczema dermatitis set therapeutics market

---

Atopic Dermatitis Drugs Market to grow by USD 4.7 billion from 2022-2027 | North America to account for 36% of market growth- Technavio
Published: 2023-10-17 (Crawled : 05:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -25.67% | O: -0.27% H: 1.38% C: 0.83%
VTRS | News A | $11.55 1.67% 1.65% 7.2M |

Health Technology

| 21.96% | O: -0.95% H: 1.81% C: 0.53%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 1.56% | O: 0.2% H: 0.44% C: -0.56%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 13.44% | O: -0.32% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -13.15% | O: -0.4% H: 0.0% C: 0.0%
PHGE | $0.3274 -5.51% 3.82% 130K |

Health Technology

| 13.33% | O: 5.0% H: 3.17% C: -1.56%
america dermatitis market

---

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 12.32% | O: -0.08% H: 0.0% C: 0.0%
abbvie dermatitis rinvoq

---

Dermatitis Global Market Research Report 2023: An $8.57 Billion Market by 2027 - Long-term Forecasts to 2032
Published: 2023-03-20 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 17.94% | O: 1.07% H: 0.0% C: -0.06%
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -1.13% | O: 0.98% H: 0.0% C: 0.0%
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -31.77% | O: -0.5% H: 1.38% C: 1.23%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 19.66% | O: 0.78% H: 0.74% C: 0.72%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 19.93% | O: 1.38% H: 1.16% C: 1.13%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 8.81% | O: 0.19% H: 1.18% C: 1.04%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -0.41% | O: 0.4% H: 0.0% C: 0.0%
report dermatitis research global market

---

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
Published: 2022-01-14 (Crawled : 19:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| Email alert Add to watchlist
rinvoq fda atopic dermatitis dermatitis children order

---

AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 54.17% | O: 0.33% H: 1.12% C: -1.22%
dermatitis atopic dermatitis

---

European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2021-08-24 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 40.58% | O: 0.3% H: 0.0% C: -0.03%
treatment europe dermatitis atopic dermatitis

---

Global Atopic Dermatitis Drugs Market Report 2021: Rising Incident of Food Allergies Intensifying Atopic Dermatitis - Forecast to 2026
Published: 2021-08-19 (Crawled : 23:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 5.53% | O: -0.56% H: 0.87% C: 0.7%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| -2.27% | O: -0.17% H: 0.67% C: 0.26%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 178.18% | O: 0.01% H: 0.0% C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -28.68% | O: -0.04% H: 0.0% C: 0.0%
BHC | $8.56 0.35% 0.0% 2M |

Health Technology

| -69.32% | O: 0.04% H: 1.71% C: 0.18%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 42.29% | O: 0.14% H: 1.16% C: 0.61%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -9.61% | O: 0.74% H: 0.0% C: 0.0%
food dermatitis drug atopic dermatitis

---

JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2021-08-04 (Crawled : 19:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 44.34% | O: -0.4% H: 0.64% C: -0.6%
dermatitis phase 3 atopic dermatitis dupixent

---

AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
Published: 2021-07-16 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 43.2% | O: 0.62% H: 0.36% C: -0.35%
treatment dermatitis atopic dermatitis

---

CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published: 2021-06-25 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 46.24% | O: -1.6% H: 0.61% C: 0.07%
treatment dermatitis approval chmp atopic dermatitis

---

The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis
Published: 2021-05-24 (Crawled : 13:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 44.51% | O: 0.4% H: 0.19% C: -0.58%
results dermatitis phase 3 atopic dermatitis lancet

---

AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Published: 2021-04-02 (Crawled : 22:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| Email alert Add to watchlist
new drug treatment dermatitis drug atopic dermatitis

---

RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2020-12-10 (Crawled : 14:12) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 54.41% | O: 0.36% H: 0.01% C: -1.44%
dermatitis phase 3 atopic dermatitis dupixent

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---